Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience.

MLA

Giordano, Silvia, et al. “Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience.” Journal of Clinical Medicine, vol. 12, no. 24, Dec. 2023. EBSCOhost, https://doi.org/10.3390/jcm12247503.

APA

Giordano, S., Dapavo, P., Ortoncelli, M., Stroppiana, E., Verrone, A., Quaglino, P., Ribero, S., & Mastorino, L. (2023). Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience. Journal of Clinical Medicine, 12(24). https://doi.org/10.3390/jcm12247503

Chicago

Giordano, Silvia, Paolo Dapavo, Michela Ortoncelli, Elena Stroppiana, Anna Verrone, Pietro Quaglino, Simone Ribero, and Luca Mastorino. 2023. “Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience.” Journal of Clinical Medicine 12 (24). doi:10.3390/jcm12247503.